



PRESS RELEASE

AVIOR TO PARTICIPATE AT THE LIVE FORUM: INVEST IN CURES (A Disease Foundation Forum) on FEBRUARY 24, 2022, 9AM – 1PM EST

CARY, N.C., Feb 22, 2022 – Dr Niraj Vasisht, President and CEO, Avior Bio Inc. will participate in a panel discussion on “[Innovation in Rare Disease](#)” with four other North Carolina-based company founders working in the rare disease space. During the panel discussion, from 10:00am - 10:40am, on February 24, 2022, each of the founders will provide information about their science, milestones, and path to commercialization. The session is moderated by Dr Christy Shaffer, General Partner, Hatteras Ventures Partners.

Investors interested in a one-on-one meeting with Avior should contact Dr Vasisht at 919.234.0068.

Avior Bio

Avior Bio is a clinical-stage, pharmaceutical company advancing therapies for the treatment of pruritus (itch) and inflammatory skin disease in rare diseases. Our lead product – AV104 buccal film – is the first-in-kind, dual-action, product to treat pruritus in primary biliary cholangitis (PBC). PBC is a rare disease.

Avior brings two innovative solutions to the development of AV104. First, our drug has a dual-action – it blocks the neuropeptide that transmits the itch response, and it inhibits the inflammatory cytokines that otherwise cause inflammation. Second, Avior uses its transmucosal delivery technology - to bypass the liver.

Avior recently completed non-clinical studies and two Phase I studies demonstrating superlative performance and enabling our Phase II clinical program. We are exploring Series A funding for up to \$24M to complete our NDA submissions with multiple, milestone-dependent inflection points. For further information about Avior Bio Incorporated, visit their website at www.AviorBio.com

Invest in Cures

Invest in Cures explores how disease foundations and social venture funds are accelerating the commercialization of early-stage technologies and therapies. [LaunchBio](#) and [the North Carolina Biotech Center](#) welcome researchers, advocates and investment professionals from leading disease foundations that have successfully partnered with local start-ups focused on oncology and rare disease.